Abstract: Personal cleansing compositions comprise (A) a cleansing phase containing a surfactant and water; and (B) a separate benefit phase containing a hydrophobic material; wherein the cleansing and benefit phases are packaged together and are in physical contact. The two phases are packaged in physical contact and remain separate and stable at ambient conditions for at least 180 days. These compositions and corresponding methods provide improved cosmetics, skin feel, and/or skin benefit efficacy.

Abstract: A personal care composition is disclosed comprising abrasive particles. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.

Abstract: The present invention relates to the field of making up and/or caring for the skin and is targeted in particular at providing a fluid care and/or make-up cosmetic composition in the form of a water-in-oil emulsion dedicated to the skin comprising a fatty phase, an aqueous phase and at least one dimethicone copolyol, the aqueous phase forming 40 to 60% by weight, with respect to the total weight of the composition, and comprising at least 5% by weight, with respect to the total weight of the composition, of at least one C2 to C8 monoalcohol.

Abstract: A changing color composition in the form of a gel for caring for and/or making up keratin materials is disclosed. The composition comprises in a physiologically acceptable medium, a) from 0.1 to 10% by weight preferably from 0.5 to 10% more preferably from 1 to 5% by weight relative to the weight of the composition of microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer at least one colorant, and advantageously at least one lipid-based material, b) at least 3% by weight, preferably at least 5% by weight, more preferably at least 8% by weight and advantageously at least 10% by weight relative to the weight of the composition of an aqueous phase comprising water and at least one compound chosen from polyols, glycols and C2-C8 monoalcohols, and mixtures thereof, and c) at least one hydrophilic gelifying agent.

Abstract: The present disclosure relates to a surfactant-containing preparation comprising one or more alcohols and one or more anionic surfactants, wherein the preparation is an O/W emulsion, the particle size distribution for which the following applies: D(v, 0.9)=40 ?m or less, and wherein the total quantity of the one or more alcohols in the preparation is selected in such a way that the preparation, compared to a comparison preparation which having an otherwise identical composition does not comprise any alcohol of the formula (I), has an increased viscosity at 22.7 ° C. Also disclosed are methods for producing the preparation and methods for increasing stability and/or viscosity of an emulsion.

Abstract: Disclosed herein is an antibacterial cleansing composition. The cleansing composition is free of triclosan and comprises lactic acid/lactate, at least one C2 to C3 alcohol, and glutamate diacetate. Lactic acid/lactate is present in the composition in an amount of about 5 weight percent (wt %) to about 15 wt %, based on the total weight of the composition. The C2 to C3 alcohol is present in an amount of about 1 wt % to about 20 wt %, based on the total weight of the composition. Glutamate diacetate is present in an amount of about 0.05 wt % to about 5 wt %. The pH of the composition is about 4 to about 5. The triclosan-free cleansing composition according to the invention has superior antibacterial activity that surpasses comparable triclosan-free formulations that do not contain glutamate diacetate.

Abstract: The present invention relates to a gel-like composition for a cosmetic preparation including 0.05 part by mass to 3 parts by mass of a compound represented by the following general formula (1) with respect to 100 parts by mass of water, which is not destroyed by a change in pH or by the addition of a salt into the gel, and gives a feeling of use equivalent to that of a gel produced using an alkali thickening type gelling agent. where, R1 and R2 each represent an alkyl group having 28 to 36 carbon atoms, R3 and R4 each represent a hydrocarbon group having 4 to 13 carbon atoms, m and n each represent a number from 10 to 500, x represents a number from 1 to 1,000, and y represents a number from 0 to 10.

Abstract: The present invention relates to compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active and a C8-C24 alcohol ester of a carboxylic acid.

Abstract: An arctigenin derivative used for anti-aging treatment, including protection of the skin from the sun and recovery of skin elasticity. A variety of fatty acid ester derivatives, alcohol ether derivatives and alkylated derivatives are used as the arctigenin derivatives. Agents for controlling ET-1 production, elastase inhibitors, and anti-inflammatory agents are prepared. Such arctigenin derivatives are particularly useful as an external agent for the skin, such as an anti-inflammatory external agent, a sunscreen external agent, or an external agent for recovering elasticity.

Abstract: A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and treat bone disorders.

Abstract: Methods of preparing a dentifrice comprising polymer matrix film with menthol therein are disclosed. The methods comprise combining a polymer matrix film that comprises hydrophobic additives and is free of a low solubility flavorant such as menthol with a dentifrice base comprising a low solubility flavorant such as menthol and maintaining the combined polymer matrix film with the dentifrice base comprising low solubility flavorant for an amount of time sufficient for an amount of a low solubility flavorant to transfer from the dentifrice base comprising low solubility flavorant to the polymer matrix film and establish an equilibrium of menthol concentration between the polymer matrix film and the dentifrice base. Products comprising low solubility flavorant-free polymer matrix film in a dentifrice base comprising low solubility flavorant are also disclosed.

Abstract: A water-based pigmented preparation, its production and use and its application in a capillary storage system.

Abstract: Described herein are oral compositions comprising an extract obtained from Arialaceae, Zingiberaceae, Lamiaceae, Fabaceae, Solanaceae, Punicaceae. Asteraceae or mixtures thereof; Their uses for alleviating dry mouth is also described.

Abstract: Methods of using WIPI-1 to impart anti-aging benefits to the skin and/or improve skin conditions resulting from reduced autophagy activity.

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic dissolved in a solution comprising an extractive solvent, e.g., DMSO or NMP, in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered as a regional anesthesia to a subject to anesthetize a portion the subject prior to a surgery, hi certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, or mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

Abstract: An acicular body includes a support base, and a needle formed on the support base and containing a chitosan derivative.

Abstract: The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.

Abstract: A dysphagia improving composition characterized in that a substance having an inhibitory action on an angiotensin converting enzyme, which is a degrading enzyme of substance P, is administered locally in a dosage not influencing blood pressure, and a pharmaceutical for improving dysphagia containing the composition.

Abstract: Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein.

Abstract: Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin in a ratio ranging from 1:8 to 1:20.

Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.

Abstract: The present invention relates to a stable pharmaceutical composition for sublingual administration comprising a therapeutically effective quantity of an antihistamine agent, in particular Dimenhydnnate and a process for the preparation thereof.

Abstract: The present invention inter alia relates to a method of treating or preventing an arterial insufficiency, where an NO donor is administered in an intermitting manner to a subject in an amount of effective for the induction of arteriogenesis, and wherein the NO donor is a solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate (GTN), at least one diluent, one carrier material, and at least one substance that reduces the volatility of GTN, whereby this substance is a non-volatile ester stabilizer whose melting point is not higher than 60° C.

Abstract: A drink for moderating blood glucose levels produced by a meal in a human subject suffering diabetes or impaired glucose tolerance (IGT) the drink comprising: at least one water soluble or water dispersible compound selected from the group consisting of amino acids, peptides and proteins in a total amount of at least 8 g on a dry weight basis per serving of drink; aqueous liquid in an amount of from 70 ml to 400 ml (preferably in an amount of from 100 ml to 250 ml and more preferably from 125 ml to 175 ml) per serving, and wherein the drink exhibits shear banding when subject to the shear banding test herein described.

Abstract: Compositions of reagents are formed by forming empty liposomes, mixing the thus-formed liposomes with a sugar solution and a regent, then drying the mixture. The compositions will generally contain less than 10% w/v sucrose. Using this procedure small liposomes are formed with high entrapment efficiency. The process is useful in the production of pharmaceuticals.

Abstract: The aim of the invention is to preserve the morphology of bicelles in high-water-content environments. For this purpose, the invention relates to a liposome comprising, in its internal aqueous medium, at least one bicelle. The bicelles concentration in said aqueous means is between 5 and 25% dry weight in relation to the end liposome. The invention also relates to the use of said liposomes for the encapsulation of active principles, as well as to the use thereof as a medicament or to produce a cosmetic product. The invention further relates to the method for obtaining said liposomes.

Abstract: The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-lactate) that is crosslinked by at least one hydrolysable monomer. Another embodiment of the present invention is a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent. Another embodiment of the present invention is a polymer particle comprising, a crosslinked copolymer comprises structures represented by Formulas (I), (II), and (III), where Formulas (I), (II) and (III) are defined in the specification. Yet other embodiments of the present invention include a method of preparing a methacrylate terminated macromonomer, a method of preparing a crosslinking agent, and a method of preparing a therapeutic agent loaded nanosphere by dispersion polymerization.

Abstract: The present invention relates to a process for the production of discrete solid extruded particles comprising emulsion droplets, to such particles as well as to the use of such particles in food, feed, pharmaceutical and personal care applications.

Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.

Abstract: The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to pediatric treatment regimens, the treatment of the elderly and non-human animals.

Abstract: Fibrinolytic nanoparticles including a polymeric core having a surface that is functionalized with a cationic amphiphilic compound, and a fibrinolytic agent dispersed within the core, are described herein. The fibrinolytic nanoparticles can be used in method of dissolving a blood clot in a subject by administering to the subject a therapeutically effective amount of fibrinolytic nanoparticles.

Abstract: The invention provides polymer compositions for cell and drug delivery.

Abstract: The present disclosure is drawn to an adhesive peel-forming formulation for dermal delivery of a drug, comprising a drug, a solvent vehicle, and a polymer peel-forming agent. The solvent vehicle can comprise a volatile solvent system comprising one or more volatile solvent, and a non-volatile solvent system comprising two or more non-volatile solvents. The non-volatile solvent system can have a solubility with respect to the drug that is within a window of operable solubility such that the drug is deliverable at therapeutically effective rates over a sustained period of time.

Abstract: The present invention relates to a method for adjunctive treatment of cancer by using a Lycogen composition to inhibit metastasis, comprising administering a Lycogen composition to the subject, wherein the Lycogen composition comprises an effective amount of a Lycogen extract, wherein the Lycogen extract comprises active ingredients selected from ?-carotene, neurosporene, spheroidenone, methoxyneurosporene or a combination thereof.

Abstract: A composition based on ubidecarenone, or coenzyme Q10 or CoQ10, comprises CoQ10, one or more specific hydrophylic carriers selected from the maltodextrins class and one or more adjuvant agents selected from the sucrose-esters class.

Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.

Abstract: Compounds of formula (I): and pharmacologically acceptable salts and pro-drugs thereof, wherein the variables are as defined in the specification, are potassium ion channel modulators, making them particularly useful in treating and preventing conditions such as pain, lower urinary tract disorders and the like.

Abstract: Suggested is a pharmaceutical composition, comprising menthane carboxylic acid-N-(4-methoxy-phenyl)-amide.

Abstract: The present invention provides novel methods for treating a pulmonary disease state in mammals by up-regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator and a pharmaceutical agent. The inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-?, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors. The pharmaceutical agent is selected from the group comprising anti-bacterial agents, anti-virals, anti-fungals, anti-tumors, antihistamines, proteins, enzymes, hormones such as insulin, non-steroidal anti-inflammatories, cytokines, steroids, and nicotine.

Abstract: The present disclosure provides solid compositions comprising a stabilized salt of aminocarboxylic acid. Pharmaceutical compositions comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate in combination with appropriate additives are also provided.

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Abstract: The invention encompasses intravenous pharmaceutical compositions containing omega-3 fatty acids and methods of treating traumatic brain injury, traumatic spinal cord injury and/or stroke using these pharmaceutical compositions.

Abstract: The invention relates to a composition comprising a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The composition can be used for enhancing the activity of chemotherapy or radiotherapy and/or in the prevention or reduction of side effects caused by the chemotherapy or radiotherapy in a patient ill with cancer, the composition being intended for administration to the patient prior to the commencement of a cycle of chemotherapy or radiotherapy.

Abstract: Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA at a ratio of about 5:2. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.

Abstract: The present invention provides a method of inhibiting the growth of or promoting differentiation and destruction of cancer stem cells (CSCs) comprising contacting the cancer stem cells with a compound having the structure: or a pharmaceutically acceptable salt thereof.

Abstract: Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

Abstract: The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor.

Abstract: The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent.

Abstract: Provided is a composition containing myricetin or a pharmaceutically available salt thereof as an active ingredient. The composition increases exercise capacity and enhances physical strength. In addition, the composition prevents aging and recovers from fatigue. The composition increases energy efficiency by improving the function of mitochondria, and also has an antiobesity effect by increasing energy consumption. Therefore, the composition may be significantly applied in a functional food or medicine field.